HOME >
Significant achievements > Immunogenicity of Whole-Parasite Vaccines against Plasmodium falciparum Involves Malarial Hemozoin and Host TLR9 (Associate Prof. Coban in
Cell Host & Microbe)

Immunogenicity of Whole-Parasite Vaccines against Plasmodium falciparum Involves Malarial Hemozoin and Host TLR9 (Associate Prof. Coban in Cell Host & Microbe) | Jan. 21, 2010 |
Associate Prof. Coban's research was published in
Cell & Host Microbe.
Immunogenicity of
Whole-Parasite Vaccines against Plasmodium falciparum Involves Malarial
Hemozoin and Host TLR9
Hemozoin: Malaria's

Built-In

Adjuvant and TLR9 Agonist
While whole-parasite vaccine strategies for
malaria infection have regained attention, although their immunological
mechanisms of action remain unclear. We found in this study that:
- Crude extract from blood stages of P. falciparum is
effective as a whole blood-stage parasite vaccine via TLR9.
- The malarial heme-detoxification byproduct, hemozoin, but not
malarial DNA, acts as a 'built-in' adjuvant.
- Both synthetic and natural hemozoin bind directly to TLR9 and induce
conformational changes in the receptor.
- The adjuvant effect of synthetic hemozoin depends on its method
of synthesis and particle size.
- Natural and synthetic hemozoin use different receptors for
their adjuvant effect
- The adjuvant function of synthetic hemozoin was further
validated in a canine anti-allergen vaccine and malaria vaccine models.
Hemozoin, both in synthetic and native form, can influence adaptive immune
responses to malaria infection, and may have therapeutic value in vaccine
adjuvant development.
